Role of the ACTH test and estimation of a safe dose for high potency steroids in vitiligo: A prospective randomized study

Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary...

Full description

Saved in:
Bibliographic Details
Published in:Indian Dermatology Online Journal 2014-04, Vol.5 (2), p.117-121
Main Authors: de la Fuente-García, Alberto, Gómez-Flores, Minerva, Mancillas-Adame, Leonardo, Ocampo-Candiani, Jorge, Welsh-Lozano, Oliverio, Pérez, Jesús Zacarías Villarreal, González-González, José Gerardo, Lavalle-González, Fernando
Format: Article
Language:English
Subjects:
ACTH
Adrenal insufficiency
Corticosteroids
cortisol
Original
Topical medication
topical steroids
vitiligo
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Topical corticosteroids are used as first line of therapy for vitiligo, although side effects such as adrenal insufficiency are possible. To establish the role of ACTH test before, during, and after treatment with high potency topical steroids; to determine if adrenal insufficiency occurs secondary to the use of high potency topical steroids in patients with vitiligo and intact cutaneous barrier; and also to determine response to treatment and side effects. Forty-four adults with non-segmental vitiligo affecting 20% or less of the body surface area were included and randomized to receive topical clobetasol propionate 0.05% cream (group 1) or placebo (group 2) for 12 weeks, with a maximum dose of 50 g per week. The placebo group was crossed over after week 6 and started on clobetasol until completion of the study. Serum cortisol levels with the 1 μg ACTH test were determined at baseline and on weeks 6 and 12. No adrenal insufficiency was detected nor statistical significance was achieved when comparing cortisol levels between and within the groups at baseline and weeks 6 and 12. Group 1 had a better response to therapy but with more side effects. Doses of 50 g or less per week of clobetasol during a period of 12 weeks are safe on adult vitiligo patients, although local side effects are possible. Repigmentation rates were incomplete with single steroid therapy, making combined therapy a better option.
ISSN:2229-5178
2249-5673
DOI:10.4103/2229-5178.131071